MX2024006746A - Métodos de uso de agentes de interleucina-2. - Google Patents
Métodos de uso de agentes de interleucina-2.Info
- Publication number
- MX2024006746A MX2024006746A MX2024006746A MX2024006746A MX2024006746A MX 2024006746 A MX2024006746 A MX 2024006746A MX 2024006746 A MX2024006746 A MX 2024006746A MX 2024006746 A MX2024006746 A MX 2024006746A MX 2024006746 A MX2024006746 A MX 2024006746A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- interleukin
- agents
- transplant rejection
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284978P | 2021-12-01 | 2021-12-01 | |
| US202263348201P | 2022-06-02 | 2022-06-02 | |
| PCT/US2022/080728 WO2023102463A1 (en) | 2021-12-01 | 2022-12-01 | Methods of using interleukin-2 agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006746A true MX2024006746A (es) | 2024-08-09 |
Family
ID=84981477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006746A MX2024006746A (es) | 2021-12-01 | 2022-12-01 | Métodos de uso de agentes de interleucina-2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240041981A1 (https=) |
| EP (1) | EP4440598A1 (https=) |
| JP (1) | JP2024543209A (https=) |
| KR (1) | KR20250169356A (https=) |
| CN (1) | CN120131911A (https=) |
| AU (1) | AU2022399832A1 (https=) |
| CA (1) | CA3238574A1 (https=) |
| MX (1) | MX2024006746A (https=) |
| TW (1) | TW202333772A (https=) |
| WO (1) | WO2023102463A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
| WO2025221954A1 (en) * | 2024-04-17 | 2025-10-23 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
| CN119638850A (zh) * | 2024-11-07 | 2025-03-18 | 浙江大学 | 双特异性细胞因子融合蛋白及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| CA2982362A1 (en) * | 2015-04-10 | 2016-10-13 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
| JP7422480B2 (ja) | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性t細胞の増殖のためのインターロイキン-2変異タンパク質 |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| JP2020530280A (ja) * | 2017-07-03 | 2020-10-22 | トルク セラピューティクス, インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
-
2022
- 2022-12-01 AU AU2022399832A patent/AU2022399832A1/en active Pending
- 2022-12-01 CN CN202510086918.0A patent/CN120131911A/zh active Pending
- 2022-12-01 US US18/060,725 patent/US20240041981A1/en active Pending
- 2022-12-01 KR KR1020247021478A patent/KR20250169356A/ko active Pending
- 2022-12-01 EP EP22843966.7A patent/EP4440598A1/en active Pending
- 2022-12-01 TW TW111146169A patent/TW202333772A/zh unknown
- 2022-12-01 MX MX2024006746A patent/MX2024006746A/es unknown
- 2022-12-01 JP JP2024532776A patent/JP2024543209A/ja active Pending
- 2022-12-01 CA CA3238574A patent/CA3238574A1/en active Pending
- 2022-12-01 WO PCT/US2022/080728 patent/WO2023102463A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3238574A1 (en) | 2023-06-08 |
| AU2022399832A1 (en) | 2024-06-06 |
| EP4440598A1 (en) | 2024-10-09 |
| KR20250169356A (ko) | 2025-12-03 |
| JP2024543209A (ja) | 2024-11-19 |
| TW202333772A (zh) | 2023-09-01 |
| WO2023102463A1 (en) | 2023-06-08 |
| CN120131911A (zh) | 2025-06-13 |
| US20240041981A1 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006746A (es) | Métodos de uso de agentes de interleucina-2. | |
| EA201992610A1 (ru) | Экспансия -t-клеток, композиции и способы их применения | |
| EA202091809A1 (ru) | Агонистические антитела против pd-1 и их применение | |
| MX2022011676A (es) | Proteinas de fusion de il12 con enmascaramiento y metodos para su uso. | |
| EP4442278A3 (en) | Humanized antibodies against c-kit | |
| PH12020551019A1 (en) | IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| BR112018076306A2 (pt) | composições e métodos para a supressão de células cd117+ | |
| EA202091219A1 (ru) | Культивирование плаценты с целью выделения экзосом | |
| PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
| JOP20220036A1 (ar) | ميوتينات إنترلوكين-2 لتمديد الخلايا التائية التنظيمية | |
| WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
| MX2022012471A (es) | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. | |
| MX2024001243A (es) | Composiciones y metodos para el tratamiento de melanoma. | |
| MX2022011163A (es) | Conjugados de polipeptidos de interleucina-2 y sus usos. | |
| WO2018220489A3 (en) | METHODS OF OBTAINING CELLS FROM HUMAN OMBILICAL POST-PARTUM CORDON ARTERIAL TISSUE | |
| ZA202100888B (en) | Methods of preparing personalized blood vessels | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| MX2023006651A (es) | Tratamiento de la hemofilia con fitusirán. | |
| MX2023006599A (es) | Metodos de uso de agentes de interleucina-2. | |
| WO2021101273A3 (ko) | 조절 t 세포 배양용 조성물 및 이의 용도 | |
| EA201992343A1 (ru) | Замещенные бициклические гетероциклические соединения в качестве ингибиторов надфн-оксидазы | |
| ZA202204386B (en) | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | |
| JOP20230034A1 (ar) | مثبطات إفراز البروتين | |
| PH12022552041A1 (en) | Anti-axl antibodies and compositions | |
| WO2021041592A8 (en) | Methods of treating vascular diseases |